Veracyte (VCYT) 2 Nov 222022 Q3 Earnings call transcript

Good day, and thank you for standing by. Welcome to the Veracyte Third Quarter 2022 Financial Results Conference Call. At this time all participants’ are in a listen-only mode. After the speakers’ presentation there will be a question-and-answer session. Please be advised at today's conference is being recorded. to Gorman, conference Director like speaker to now Shayla today, of would hand over the your I Investor Relations. ahead. go Please

Good press are Medical Global President This U.S. this at Dr. our Marc release Investor Scientific Chief website a Veracyte.com. joining of our for a Veracyte's and Chief presentation, of our XXXX And Veracyte Kennedy, Officer; the quarter Rebecca for Stapley, news results. results. Giulia everyone. available Chambers, Officer; section financial financial today discussion is quarter with earlier our and Dr. Chief detailing us me financial CLIA With Financial Business; Executive a third Officer. third afternoon, Chief today along our business afternoon and of Relations in thanks Tina issued Officer XXXX Nova, release,

remind we forward-looking will that you various like statements as call securities statements I'd defined applicable Before we this include make the laws. begin, during to may that under

and statements not under no be further are our subject we Forward-looking could the performance trends are that Forms you XX-Q the prove and Further quarter. including cause recent business obligation most the XX-K. Commission, correct. we during Veracyte's filed risks To uncertainties to to our they Securities and will updates assurance differ, and provide any can or to give company actual the on with risks to uncertainties better to Veracyte that results documents understand refer the and Exchange

are today's release, IR Veracyte's turn most Reconciliation over will these call website. addition, the the measures include measures. in section Marc to will Veracyte, the earnings measures comparable financial I this Stapley, directly CEO. of from to of now certain financial non-GAAP call accessible GAAP In included

Thanks, us Shayla, thanks, joining everyone, today. for and

in of highly vision. to %XX.X team, test, strong the valuable and execution while potential also XX% achieving of year-over-year With long-term was delivered respects our growth million. realize our we strategic revenue first quarter continue and of advancing we our growth incredibly outstanding all Our by CLIA opportunities

represents quarter sequentially. traction exceeding our of in business, and in revenue We reported tests third as out and to endocrinology anticipated our double-digit testing we urology XX% up play seeing grew core which the our XX,XXX not Our in over quarter expectations. seasonality over used Decipher did the market are The strengthened. quarter, XX% this Prostate

investment coupled team market coverage just share majority world-class in with believe reimbursement continuous clear over is Our evidence have in penetrated. commercial is off. of that expansion that resulting a in guideline cycle XX% a now clinical paying We broader our and we

With the strong broadest should be indication conviction have any indications, test continue receiving we for and coverage of those men with guidelines prostate most to testing. of that cancer decisive positive many

may diagnosed available with indicated expand to evidence therapy understood STAMPEDE of potentially Prostate development many to have into with will we Decipher currently. a that Phase metastatic We Prostate market reimbursement record XX% help to be findings on of enable coverage commercially decision-making evidence over the executing of advanced cancer growth even in were top test which regarding making come. is of to intensification proven well point, body more This to that playback Decipher X prostate men indication, will the of trial. this track fueling from the the test data the the Decipher released quarter, us for years used during These to use key test To for durable multicenter, cancer. penetration, multinational suggest achieve the inform of adds a for prostate the patients

and is and the With cycle XXX Society with many body far so to into clinical coverage. test a Afirma tests cancer using Institute period. of an an and Cancer Network the podium be the guideline believe Journal the more American We has signature the National Annual XX for Again, market prior thyroid evidence This presented Decipher or inclusion grid team. compared patient we Comprehensive quarter, unparallel. of results grow at test National more payer led derived continues the growth publications enhanced our the support, revenue our study quarter be strong test thyroid supporting and talented the Meeting. account. to of were Cancer Decipher had in XX launched nodule. its market commercial database evidence patients is to Last number a defining we presentations, the with indeterminate development now from genomic the to terms quarter Additionally, market to our data reimbursement, in on genomic this close Radiation in thyroid decisions added the and published evidence payers, Afirma, to during over this Oncology it ordered Thanks was major commercial reimbursement drive strongest Prostate for increase members out NCCN further. define further not Decipher, received been inclusion positive whether cancer. to evidence XX% level Afirma per that believe in expression Afirma penetrated leading million. room and commercial delivered the covered the at prostate through leading a new we number and the carry any quarter, We updated over team managed test test making the was to and year ago the bringing evidence Decipher achieve its X%, market expand million in accounts that new than representing to the the continues genomic saw on of for lives XX surgery cancer cancer. test time of one KOL a guideline first with help inclusion We quarters, of to XX-years our presented coverage to year Further who experienced determine for over test and recently from care guidelines, test. total utilizing of gene only guideline status several prostate has last three a

We million members, offering XX to additional payer plans with be million four the XXX experienced plan total adding continued also payer over to in regional more lives. for health Afirma large traction contracts enabling than network bringing

plan Additionally, launched customers, track tests increase our their customers, results patient Afirma way new enhancement we a physicians internal use order portal near supplies view our convenient patient the a product the a This our and online. of to samples, first we number that and in of results, test efficiencies. staff future providing enhance for to for launch time ease order for will online accelerate to and the

which American insights new thyroid uncover were insights ability capabilities. Afirma. of Conference, Thyroid to expensive further Finally, to we new by next demonstrated fuel share excited our our at we research help differentiate upon the innovation believe and our such thyroid could and cancer phase transcriptome drawing in cancer Ultimately, that whole the Association care database

us to growth of high accomplishments continue All XXXX. meaningful confidence Afirma the will give in to mid that deliver these revenue single-digits in

we new to checkpoint continue we partner's to which and our pioneer Moving oncology, in believe others. immune treatments CAR biopharmaceutical inhibitors help business, immuno our T-cell advanced will frontiers such edge therapy, biopharma as cutting

among T-cell This large proprietary in an B-cell quarter help Nature patients offerings to CAR for therapy. point an the immune suggested and important These our make predefined could with example, is therapy paper how benefit between benefit this proof published from multiomics these study biopharma technology first to For lymphoma, patients. provide biomarkers expertise our that can findings connection this who our will and distinguish response partners. exciting such Medicine

Utility same reminder, us generation, gives and numerous opportunities various of the with Looking the in for to Chest Nasal enrollment of patient the approach Nightingale Nightingale or Test official with last Nasal commercial We progressing long-term Swab at are time, and instrument. plans Swab Nasal transform stage believe is our Swab phases completion of deployment At primarily well Annual next Vitro Meeting and focused drive for from early opportunities The the commercialization data preliminary Decipher our nCounter our in of Percepta evidence test classifies for with we shared Clinical aforementioned year. the forward, development cancer, and products treatment well diagnosis growth Study with risk so reimbursement procedures test development as avoid our [Technical broad or on As care In end lung strong multiple our unnecessary and more Difficulty] Diagnostics portfolio as for they Percepta potentially lung more growth. IVD cancer, suggesting necessary, Envisia, in high more low improvement versions to of risk, patients so standard-of-care. the test our revenue to timely as patients to investments with month if they a and can that compared proceed the can

the are we Classifier regulatory first of launch IVD on On Envisia our XXXX. are our forward and to those, looking in submitting menu, programs track for our the product all test three global of EU approval Genomic of development

Society made We achieving further Conference, data of our summary, in deliver by vision. on presented strong that strategic tangible towards business Annual building great compelling clinicians In Respiratory team were a results important quarter test awareness we are in Europe. the among encouraged the had our which executed Envisia our to the at European strides current and long-term

tests, outcomes We call our to that, via exceptional to results I Veracyte. profitability our future the for turn driving driving on more financial patients will to and over will for focus and now diagnostic growth Rebecca turn improved discuss continue With in detail. in

Thanks, Mark.

was of XX% and quarter driven of stellar Afirma Afirma by in increase revenue in over across Afirma million volume with situation the driven up as of well prior rearview ASP of grew Decipher year. with quarter's XX,XXX now period Testing volume increase chain another prostate mirror. same expected as slightly increase had of contracting increase total X% a delivered we the over improved said, test. in the payer our approximately tests, summer an despite tests, sequentially. Mark primarily expectations higher over sequentially XX% testing and $XX.X typical an by million, mix, last $XX.X seasonality, We to revenue, Decipher and As supply volume a year-over-year, XX% on XX,XXX We than XXXX,

in having with usually different. quarter services approximately currency resulting of the year-over-year, prior Biopharmaceutical and and making of with impact the anticipated. was this smaller year remainder business revenue than a million, IVD no up $X.X of given expectations volume XX% seasonality this rates. was headwind over The about contributes of revenue line totaled million biopharmaceutical up and a in tests, revenue X,XXX other XX% $X.X ahead product manufacturing quarter Third despite half

exclude Moving assets, amortization margin to include up was points was Product compensation. margin basis results, acquisition-related XX does other intangible Non-GAAP sequentially, approximately the margin I quarter. compared of sequentially. expenses, routine gross costs, but restructuring and flat highlight margin XX%, to and expenses was will XX% the gross lower non-GAAP gross acquired X% operating which testing gross stock-based prior

ahead France goal. Importantly, progress on our transfer as we've manufacturing year our now of end fulfilling made Prosigna out of we're great kits

Sales As and short excluding to net with million. gross lower saw any which cash, due expenses compensation. operating gross We overall million sequentially of product commission million marketing higher the of by a transition and million, down driven quarter $XX.X development to expense with of product and loss cash million was were Non-GAAP set investments. to $XX.X Research mix million margins. like increased to expense the as $X.X lower as expenses, $XX.X million cost position equivalents grew the G&A approximately incremental GAAP increased by which We our outperformance. the expenses $X.X of ended and $X.X some $XXX $X.X to included trial shift. stock-based expenses as million by we approximately cash costs revenue to and and million given we million. recorded up our other and project process, revenue million $X.X increased term $XX.X this, by led Biopharmaceutical well $X million, margin ramping clinical $X.X

the $XXX our of our current growth our million urology we Turning to business, XX% continued revenue currency on in range $XXX $XXX of performance revenue reflects Afirma are mid low to a previous updated year million to full-year quarter, to to compared and to our expectations strong guidance reported outperformance versus $XXX million, single-digits of or third XXXX rates. the our prior guidance, million raising XX% basis. to This full-year growth

other Biopharma and expect be project given down We timing. revenue to sequentially

expense. profitability, As long-term in we will cash believe drivers now we've impact XXXX, turn prior have acquisition-related to we continue anticipate on consideration our M&A. approximately we hand flow to barring business said the able In previously, to of of plenty will to back be cash call growth and excluding to we invest the remain neutral the Shayla. contingent take I

and and Thank Giulia please our Rebecca. join Chief Q&A go you, Scientific Medical the Business; us. call now Nova, the portion the Kennedy, We'll and Chief into Officer of Officer Operator, CLIA Global President U.S. Tina open line. of will

Instructions] comes question Stephens. One our proceed. for [Operator that moment Please Mason from first with you. Carrico Thank

Jacob just cleanup is the or from throughout guys. there and of Thanks carryover Afirma maybe quarter? vendor-related for taking Hey, issues as on to Or with entirety Mason. a vendor-related Maybe more during This questions. the the on starting volumes the of impact the that back Was XQ business less for a here. usual was it Afirma quarter?

quarter I very normal to much us third dealt third the normal and muted, us. Most of mentioned, quarter that back Yes, activity well, Rebecca and in the in very for issues with effect within think now. behind small. in of you were the quarter to that's bulk rearview as were us say about has And very that that if and positive that would as the we very the second much back get vendor like the the we so quarter to during was mirror been able affected

the as see large of year a a by Omicron. impact Afirma just And decently reminder, last quarter third for did

So that your is the mind of back something in to as keep well. just

Okay, Awesome. got it.

years the next Maybe potential business? from business contribution run the the business rating Biopharma to of so? the your what possible, the say of lot expectations your ramp -- some And maybe color been just a demand high this you're opportunity about for then and currently? then seeing from just the on recently oncology over business are If scale provide immuno and three moving long-term So Biopharma. on you size or could this talking

so publications to several our a well and as start team we assays a demand last cancer. the had colon develop customers both, of how oncology earlier, immuno More kind including supports quantification, Yes, I have ones interesting customers. we with in we've you recently, the and maybe the in Immunoscore number as about with business We've excited in jump as really nature mentioned that lung in can but and partners. and I'll want custom then our some IC Cell, that quarters, of in publication for might Rebecca of Biopharma with particular really developed great we're that the business the over CAR-T proprietary on ones of, number and

programs Difficulty]. I to development. drive then clinical towards ultimately, opportunity help demonstrates an them think at really Veracyte with identify biomarkers their [Technical point, diagnostic for to advance But trial some companion

In numbers, Rebecca? the terms revenue of

portion. Yes, I'd that be to happy take

can that company of about purposely. piece biopharma XX-XX. is you line portions the P&L. development biopharma explicitly two very other other dynamics and So in other across contract the be revenue the portion, line is see biopharma growing to should nicely. the revenue the our face Approximately of that sorry, IVD piece Biopharma very half That and different of the The Two accretive manufacturing, and business total growth. growth is is

as purposely. is The effectively we piece manufacturing very manufacturing. organization of those factor time. contract to more and contributor growth move the development of towards is necessarily for IVD going a the of revenue reason and become same that for that to use and our less the own we line, meaningful a On isn't for over And resources IVD not revenue it more

piece and it's So important with bit asset and from perspective on IVD you revenue R&D the specific track tale two being development of a businesses, being will, to verify. the of asset obviously our a for more a biopharma if strategic and efforts very strategy

milestones nature bear And everything maybe contracts lumpy and itself to Biopharma said, mind just the agreeing the Rebecca as that timing of those quarter-by-quarter add in I'll due to be just very the well. one thing side, of can but on revenue the with

growth I'm basis being about that quarterly -- think sorry, so than quarterly basis, an we on on a accretive annual And a more Absolutely. basis.

it. guys. got hop the Okay, I'll Appreciate queue. in the back color Thanks.

Thank you.

our next Thank from Blair. proceed. that Andrew you. with moment the for Brackmann William line One question, Please comes of

on questions. the beat with the Hey, for by beat is versus of Maybe raised Decipher. guys. the XX.X% quarter that so by from just about consensus, most Griffin This Good on for Thanks Andrew. X.X% guide here, afternoon.

mid-teens was a Decipher. had term about prostate you year? in big I think close you for maybe a You that talked question the talk just something get? of large pretty to like Can there yesterday competitor tests how competing XX% versus think about the longer think I numbers, that's about durability growth next just we

had standpoint, to able proud maybe product Yes, firstly, thoughts couple over are also the Afirma was and then the as demonstrating what mean, well continues on way, just an that quarter a increase also the is volume of course, a new that record and bring which on market I'm from penetrated volume. By with product both customers. ASP. extremely grow that. team keep our seeing, on has in how -- in the by, existing ability been accomplish of terms to And and the we're of upside of at I beat volume driven driving we to customers the both XX% And of working Afirma

Tina doing that, business she driving adoption more that the she's job genomic just has wants. to to doing and of any mean, add I commentary it's that going We only team Decipher. about so. and I'm expression to of, this guideline, that exceptional the similar in So majority stage the that share. and one also clearly a NCCN is is including represents development about a playbook to of we've talked Decipher, before. but earlier [indiscernible] an able just level demonstrate over On and one market And that with her through guidelines XX% story, more an guideline. been Decipher market of kind color test does level keep story, we've turn penetrated driving

that direct prostate would been that on question. in years, but continues time its think say coverage is as -- the that we to to many would Afirma, to compare the you you more comparison, was different And market It's just for for all you that to RP has if new development, then compare prostate, few continues a very think I you And gain year we because -- mentioned, Afirma for by customers three and Mark ago. Decipher on just and you. if had a biopsies do well. great like a Thank years the

we we gaining have we're year. lot believe lot a really of new of positions still So every runway, a

side, podium we're the just the only the but We evidence incredible out utility And and by others. presentations continue of clinical also level all at one product. to develop doing the presentations major posters, not really on is came meetings that validation

as I Decipher. before, think don't foreseeable we've And changing Yes. I I got the market this said headroom future room, a for for mean, I've a lot more see in of here. lot the situation

but said I As we're There's included. man few indications with here, prepared we cancer left, at every a point in getting the Decipher need where most remarks to should test. prostate the be get very

So future. plenty in of the growth opportunity for ongoing

you've Afirma then on Okay. up the single-digit And on ’XX mid following growth. to just that, high reiterated so

can we benefit that depressed Just pricing maybe following in saw expect Afirma assumption, ASP just you the half the volume year a you [Technical next of that from change? quantify the Difficulty] second

Yes.

very thing dependent XXXX necessarily we're single-digit we most quarter absolutely or in and longer because should mid takes it in get Afirma. we a know be volume high to to here, Griffin. is growth tailwind. question, important a given confident aren't the in a volume want good growth are and to the to probably of of should any tailwind parsing plenty that we're I that guiding a that's something growth get room do The to on no to you ASP be identified The highly number so little than growth. incremental the that's seeing, in penetration bit just, think I support more they for variables. market of in ASP ready With And think So it should left puts also the be will there's tailwind. that volume levels headwind be to habit a

cap just sneak kind appealing just could anything in the unique million one in How I of flow most pretty more assets If the cash what are are $X front? small M&A you diagnostics right about is plan. and appetite, thinking operating now the on Okay. that

Yes.

in terms that of the our I firstly, obviously proud strong quarter the and of $XXX fantastic. mean delivering million last very is cash in cash quarter ending obviously team of generation quarter up in So with from

the position M&A, said We've right bar of always hasn't not to high opportunities very focus and it's our we now. primary presented never terms situation, our there we're that our to themselves In M&A, ignore But changed. and is open us.

in doing growing interested a to in including But and what I'm Small about to whether and also mid-term only our some given execute that were point, things primary very be bolt-on of anything be on position. to way continuing focus focused significant cash and is path at on an Our talking We'd assets inflection be type here, long-term we're possible, we would it growth cash technology profitability. clear our accretive but drivers. would there. rate business are significance of in

to will change absorbing year say over successful a of decide there, over did I do approach we and our So our team's and in no that given if and integrations into that Decipher acquisitions year prior, now very them. developed we -- we the at experience be HalioDx we'd what do we're our

I ways to rather kind of anything drive on there. like it’s at So than said, But experiences beginning, some good the at this more point. the trying watch

guys. Thanks Okay.

Company. our proceed. Mike Thank & question, it Please for with you. line One moment Matson and of Needham the next comes from

taking first than for operating guess about significantly slower a that, solid to revenue. looks thanks so expense. and quarter. questions I congrats And It on time, while. can it wanted like the first remember Yes, I my seeing I in ask grew

growing you out it why bit can probably acquisitions was that -- a you've but so that done growing stuff, before, driving some something OpEx. leverage, know and sustain just faster So I is that was

our the cash way we're and whole start and I'll greatest generation, mean, But the operating return expenses both using effective I Rebecca I then focused, in. long-term. Rebecca mid-term responsibility and Yes, as we're for you jump on very most team in and fiscal very, the know,

over it’s mentioned work went accommodated year. to and that happy I'm about a for we the talked so they've just recently as portfolio make. reaction management. the all -- are where as And good have continue will forward. or a we do we it decisions isn't actually doing But today, to we anything, been need and made going through to been that This review we've far We've we've

And making investment we're and those reflects of level next all Rebecca? the prudent so the right that decisions, into now of year effect

completely I line we agree, And going couple absolutely. think a look I when Yes, forward, of there by are line factors. different

point On in has On endocrinology all serving an the hit teams you to about are actually obviously, see critical marketing R&D point and nail areas those priority Diffiuclty] head I leverage a portfolio. XX unique basis, time. is will for a the markets think at on continues therefore enrollment but should to of and forward the where have on people when this also incredibly urology, our more investment to and what us. you highlighted this productive the given on and markets absolutely over that G&A, sales so leverage organization to we all made comp, continue On should a around very point ramping, basis, our will a and And some of been look especially point especially we a R&D Nightingale side, one forward decisions leverage. those be structure in the ramp, for in be marketing, a pulmonology we've can as be we anyone specialty sales go go and serve pulmonology extreme you of time, expense absolutely sales extra [Technical from are the recently of that with XX than believe

XXX% there'll prudent, go OpEx. margins forward or see you out saying basis incremental be of but margins should that not dropdown be margins a on wouldn't incremental obviously So definitely

And why one, go thanks. of planning you're the that why just on nCounter the mean, kind like and guess the I run one I I Decipher the the first? first I in isn't tests the to with But probably of Europe. that in order home or tests, the know given you Decipher’s terms is mean, success IVD sequencing then Envisia Okay, new test, of of launch wouldn't

It's you this, started an is first when question and far very and at and excellent already we in advancing terms simple. look being the conformity we've acquired reason terms a with advanced to pondered the lab imagine validating we test in quite Envisia can was lot able Decipher, it code getting before our of -- and to tests. ready set, and of the demonstrate one developed existing

we've that several it. the to from it move very to ready So prostate it and journey back be along of Envisia. on to already needed so it to that perfect that test case getting just model clear forward, at able that nCounter the being a go illustration to Decipher start of it's complex and based clear on -- beginning steps work that the based done then over submitting commenced the beginning is and right? had of We was far the

responsible team the extremely because our for was next the we team we that at we there then approach great just what believe. first demonstrate Envisia, ago, the capabilities mentioned, the prove, up unmet for completed year pent to forward market well So with to use I and testing Decipher need of thought an smart And launch looked came get Halio as there and and and reason demand a this there. an prostate big over is acquisition a you over came a

swab on after year course the then nasal and of next So that. one that's the that's talk, the why

just broader really you going that kind starts kind to drive, scaling nCounter enough you Are up? Envisia, you then mean, And it think do before need, of, placements could menu there's -- with with that market that there I a enough big of, alone? a

You an in it's rare mean, you Envisia, condition. if need special disease, think more. lung about IPF, I a

and that add additional European for on need menu our to sure at teams and in it's having going that looking for have us to the to to helps test sell. it so to Decipher. the And portfolio to forward least able menu But their be

see lay nasal function. you next of a kind I on think you increase top interest you course, step the going step Decipher add in of big of And then, when swab function prostate, get the a once we forward. a that,

pretty And already base a there in significant of is installed in the recall, nCounter European instruments market.

more a about we organization much than so timeframe. the the forward is the and as the growth of to kits the of And more instrument This actual pull look placement. reagents through long-term over factors so

Yes, Got you. Thank okay. it.

moment Savant It comes next for Tejas from Stanley. One Morgan you. Thank our question. with

please. question Your

you is for Hugo Thank taking questions. This Tejas. on Hello. for our

growth share test, opportunity shift You represent the Do for mentioned some this that think for prostate potential you a in but you that's landscape. you view dynamics Decipher room be this share prostate sustainable. chance? could temporary your of specifically you? a tests and recent in Do see of see a could on classifier bump competitor the Or of shift gain with do the you lot

shift are When respect the talking about MDX with and dynamics, to in to you Health? Exact you're referring

Yes.

different. something Or

mean, yes, you. this you're pass I'll Tina, Okay, every to I it day. living over I mean,

Yes.

ahead of that because really in how test. and very to is They a that occupy. that's of and level We don't is good itself competition the that where genes we three. our are. just lot differently penetrated about very, that back physicians the about just and than and we've to the feel out we with think came that about one it different very from a much seeing the the markets and our the other customers far which that than they're very think level by guidelines, And that very different feel used for how good the have test at of we again, grid test evidence NCCN offering RUO look level setting I we the have, very have we market our

still with us. I to difference we feel the from even great that's think MDX that that market in to have position our So movements still make to And I with great don't that going Exact a position marketplace. a

Purely great.

does test how could That by elaborate for the then enrollment getting timeline readout that enroll for study study into it. helpful. on was study super stack you how that separate design up against Percepta for and the timelines expecting patients that Nightingale as caught that are you nCounter? for Giot on And have the to a many trial and And trial Swab follow-up, Nasal year-end? the up

Yes.

which But of behind very I any quarter detail progress the the But as on itself, early study at going and about because enrollment, acquisition, trial I'm relatively days as numbers far, encouraging ramp initiation design. the comes you on site give it’s would couple we're very so much as more still per more terms far sites. I'm patient site increase very seeing well, and bring pleased very mean, the of the small and numbers on reported so is is there, making, track in is I we're in with So the site more extremely that patient the a Nightingale our you quarter last to expect, team this things not in an knee stage.

So to nice see that. it's

done demonstrates get how meet of the that where of to it'll think be do we see I'm it we end the those we on internal of guideline projections enrollment. terms really getting We quarters patient are. our quarter of work numbers expect I end of in done doing a still -- own that the along XXXX by based far sorry, that end the more we've we're and start to year, final next couple that next before can

reimbursed we the back and at U.S. our OUS outside on evidence so utility and our with goes this strategy. time, our the implementation. Again, to relative and that development launched helps market. with nCounter But looking partners model even the to we're can Now clinical tests the in these ways more generate in the show same Having U.S. our certainly at U.S.

joined but nothing be that's to we’re about thinking yet, Leite John at. something that the so then reimbursement this looking our be the typical displayed in as going I it to business of just going things one comes tend GM, and is after would us that. that's test think But And a he's would and launch OUS the OUS market. the I at about stage, as U.S. model being to you pulmonology

you. Thank color. helpful super That's it. Got

Thank from it the Please proceed. please. moment next question with you. Matthew And Goldman our One Sykes line for Sachs. comes of

Dave the This for on guys. Congrats Hey, on quarter. is Matt.

for discussions more tell how future the payer expectations wins could about good some any went you going on side, commercial and discussions coverage had these You forward? us

are But add these go. tackling firmer line. work embedded the mean, start tester get in long of typically you both feel utilized to here. or plenty in hard never and of don't get from take a a I I'll is to team can first. you Yes. get well, blocking they and lot do, way a way a even to guided experienced over negotiation size very of the time go the anyone the some, there finish free the team for lot by discussions else a There's even the and a as and lot And one even or as of to when and every these

So see those in and want team job so in We've great now to nice the covered a core lives the testing pipe here. drumbeat line got products. add? many has both done more continuing of the you it's to just always Anything

it’s Decipher Yes, in is I with commercial progression that payers. would still early the just say

We continue few that evidence as and level presentations helpful We quarter very quarter. these that were mentioned securing the think well. very, of this as in more are did again, clinical one previously, And add addition the utility to done NCCN by add the extend contracts. every a our data I I

can what first Marseille, Any And forward? we Great. there transition steps great for around going completed. the manufacturing color then hear next is that wave to to additional the look

part the of mentioned day Marseille there. next we this No, fulfillment see get end the The the done. job to and is was key and that through great actual the it will over I team before of completed doing over really, nice take stuff manufacturing is as through really XXXX think to to a and transitioned

-- more don't I until any to next that. foresee we with So that to really but report end problems of on the nothing until get year, we

guys. Thanks, Great.

call conclude for Thank final will you. I'll with turn Stapley And the Marc I Q&A the back remarks. to session. that,

appreciate it. I you. Thank

Executive I’d we're talented patients all an from their into us we incredibly year commitment help and our last you strong. for support continue had and just to during of work, we Chair excellent Anderson the transitions team heard, the as hard important vantage Chairwoman, as the Board thank like also goals of her our quarter Co-founder, to execution fully next So XX-months. long-term like deep Bonnie X, on track for to Veracyte Bonnie serve. the that year. achieve January ultimately to point to she will our thank role from I'd out finish

board. to forward continuing her So and with to partner the looking I'm really

key value at diagnose to unmet delivering treat physicians insights and are addressing know, high race as Our to care matter needs, you tests that cancer. provide moments patients that exceptional enable their in to the

the clear portfolio a to be a world. around We for a of and couldn't I about have available them great more pathway formula making our them patients winning commercializing product progress excited the for With keeping for for Veracyte. look you. thank tremendous we for lie today forward to want in opportunities ahead our that, to-date you I you joining apprised us Thank to and progress.

And ladies this today. our you. you us. Thank call Thank concludes joining for gentlemen, and for

disconnect. now may You